[1]CurrentPatentAssignee:GUANGZHOUINNOCAREPHARMATECH-WO2015/48662,2015,A2Locationinpatent:Page/Pagecolumn39
[1]Patent:WO2015/48662,2015,A2
[1]CurrentPatentAssignee:GUANGZHOUINNOCAREPHARMATECH-WO2015/48662,2015,A2
[2]CurrentPatentAssignee:BEIJINGINNOCAREPHARMATECH-WO2020/173407,2020,A1
[1]CurrentPatentAssignee:GUANGZHOUINNOCAREPHARMATECH-WO2015/48662,2015,A2
[2]CurrentPatentAssignee:BEIJINGINNOCAREPHARMATECH-WO2020/173407,2020,A1
[1]CurrentPatentAssignee:GUANGZHOUINNOCAREPHARMATECH-WO2015/48662,2015,A2
Title: Wei Xu, et al. Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia. Blood (2019) 134 (Supplement_1): 4319.
Title: BTK Inhibitor ICP-022.